North Carolina Central University


John E. Scott, Ph.D.

Home | About Us | Our People | John E. Scott, Ph.D.

John E. Scott, Ph.D.
Associate Professor of Pharmaceutical Sciences

  • Earned B.S. in Biochemistry at University of Illinois and Ph.D. in Microbiology and Immunology at Duke University
  • Over seven years of pharmaceutical industry experience in drug discovery at Eli Lilly & Company and Helios Pharmaceuticals
  • Contact: jscott@nccu.edu or 919-530-7569

Cancer Research
Approximately 15-20% of breast cancers have a triple negative phenotype (negative for ER and PR expression and lack ErbB2 overexpression) that correlates with aggressive cancer and limited treatment options. The focus of current research is the identification and characterization of cell signaling pathways and kinases in triple negative breast cancer that are critical for tumor growth and metastasis.

Chemical Biology
This research is focused on developing novel chemical biology approaches to the discovery of small organic molecules as research tools and potential drug leads. We develop and validate novel biochemical and cell-based assays and use them for high throughput screening of chemical libraries to identify biologically active compounds.

PON-1 Biology
PON1 is a serum enzyme that appears to protect against atherosclerosis (i.e. hardening of the arteries) and the expression of PON1 varies considerably among individuals. The goal of this research is to better understand the regulation of PON1 expression and enzymatic activity. We are interested in novel activators of PON1 that may have therapeutic utility in atherosclerosis.

PUBLICATIONS:

2012
Ahmad, S, Hughes MA, Johnson GL, Scott JE.  2012.  Development and Validation of a High-Throughput Intrinsic ATPase Activity Assay for the Discovery of MEKK2 Inhibitors.. Journal of biomolecular screening. Abstract
Cronan, MR, Nakamura K, Johnson NL, Granger DA, Cuevas BD, Wang J-G, Mackman N, Scott JE, Dohlman HG, Johnson GL.  2012.  Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis.. Oncogene. 31(34):3889-900. Abstract
Ahmad, S, Hughes MA, Yeh L-A, Scott JE.  2012.  Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors.. Journal of biomolecular screening. 17(7):957-65. Abstract
2011
Ahmad, S, Hughes MA, Lane KT, Redinbo MR, Yeh L-A, Scott JE.  2011.  A High Throughput Assay for Discovery of Bacterial β-Glucuronidase Inhibitors.. Current chemical genomics. 5:13-20. Abstract
2010
Wallace, BD, Wang H, Lane KT, Scott JE, Orans J, Koo J S, Venkatesh M, Jobin C, Yeh L-A, Mani S et al..  2010.  Alleviating cancer drug toxicity by inhibiting a bacterial enzyme.. Science (New York, N.Y.). 330(6005):831-5. Abstract
Ahmad, S, Scott JE.  2010.  Estradiol enhances cell-associated paraoxonase 1 (PON1) activity in vitro without altering PON1 expression.. Biochemical and biophysical research communications. 397(3):441-6. Abstract
Ahmad, S, Carter JJ, Scott JE.  2010.  A homogeneous cell-based assay for measurement of endogenous paraoxonase 1 activity. Anal Biochem. 400:1-9. Abstract
2009
Larsen, RS, Zylka MJ, Scott JE.  2009.  A high throughput assay to identify small molecule modulators of prostatic acid phosphatase.. Current chemical genomics. 3:42-9. Abstract
2008
Nakamura, K, Zawistowski JS, Hughes MA, Sexton JZ, Yeh L-A, Johnson GL, Scott JE.  2008.  Homogeneous time-resolved fluorescence resonance energy transfer assay for measurement of Phox/Bem1p (PB1) domain heterodimerization.. Journal of biomolecular screening : the official journal of the Society for Biomolecular Screening. 13(5):396-405. Abstract
Graves, TL, Zhang Y, Scott JE.  2008.  A universal competitive fluorescence polarization activity assay for S-adenosylmethionine utilizing methyltransferases.. Analytical biochemistry. 373(2):296-306. Abstract
Graves, TL, Scott JE.  2008.  A high throughput serum paraoxonase assay for discovery of small molecule modulators of PON1 activity.. Current chemical genomics. 2:51-61. Abstract
2004
Sussman, A, Huss K, Chio L-C, Heidler S, Shaw M, Ma D, Zhu G, Campbell RM, Park T-S, Kulanthaivel P et al..  2004.  Discovery of cercosporamide, a known antifungal natural product, as a selective Pkc1 kinase inhibitor through high-throughput screening.. Eukaryotic cell. 3(4):932-43. Abstract
2003
Scott, JE, Carpenter JW.  2003.  A homogeneous assay of kinase activity that detects phosphopeptide using fluorescence polarization and zinc.. Analytical biochemistry. 316(1):82-91. Abstract
2001
Peng, SB, Zheng F, Angleton EL, Smiley D, Carpenter J, Scott JE.  2001.  Development of an internally quenched fluorescent substrate and a continuous fluorimetric assay for Streptococcus pneumoniae signal peptidase I.. Analytical biochemistry. 293(1):88-95. Abstract
1998
Malyguine, AM, Scott JE, Dawson JR.  1998.  The role of calnexin in NK-target cell interaction.. Immunology letters. 61(1):67-71. Abstract
1997
Scott, JE, Ruff VA, Leach KL.  1997.  Dynamic equilibrium between calcineurin and kinase activities regulates the phosphorylation state and localization of the nuclear factor of activated T-cells.. The Biochemical journal. 324 ( Pt 2):597-603. Abstract
1995
Scott, JE, Dawson JR.  1995.  MHC class I expression and transport in a calnexin-deficient cell line.. Journal of immunology (Baltimore, Md. : 1950). 155(1):143-8. Abstract
Scott, JE, Dawson JR.  1995.  Heat treatment of leukemic cell lines can increase their sensitivity to NK lysis.. Cellular immunology. 163(2):296-302. Abstract